SCHEMBL3741083

SCHEMBL3741083

CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 7/20 0.63
PPARG P37231 7/20 0.63
FABP2 P12104 2/20 0.63
SLC22A12 Q96S37 1/20 0.63
CYP1A2 P05177 4/20 0.60
CYP3A4 P08684 4/20 0.60
CYP2C19 P33261 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
CNR1 P21554 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ABCB11 O95342 2/20 0.60
TSHR P16473 2/20 0.60
HTR2A P28223 2/20 0.60
PMP22 Q01453 2/20 0.60
MAPT P10636 2/20 0.60
CYP2C9 P11712 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HPGD P15428 2/20 0.60
USP2 O75604 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704080 0.92 PPARA (0.56) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL28397895 0.89 PPARA (0.61) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL11431131 0.88 PPARA (0.62) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL2822423 0.85 NR4A2 (0.56) PPARAPPARGCYP1A2CYP3A4KMT2A
SCHEMBL28910816 0.84 PPARA (0.53) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL20704120 0.83 PPARA (0.68) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL12573590 0.83 PPARA (0.67) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL12573936 0.83 PPARA (0.86) PPARAPPARGFABP2SLC22A12CYP1A2
SCHEMBL15674282 0.82 PPARA (0.65) PPARAPPARGFABP2SLC22A12CYP1A2
Fenofibric Acid SCHEMBL10966358 0.81 PPARA (0.77) PPARAPPARGFABP2SLC22A12CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115305488-A High-energy material containing azide-tetrazole and preparation method thereof 福州大学 2022-11-08 CN disclosed
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2010-11-18 US disclosed
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2010-11-18 US disclosed
WO-2009073138-A2 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES GPR119, CPT1A, GLS2 PPARA 147/4885PPARG 134/4885FABP2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.